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Abstract 
Matrix metalloproteinases (MMPs) have been shown to be involved in tumor-induced angiogenesis. 
In particular, MMP-2, MMP-9 and MMP-14 have been reported to be crucial for tumor 
angiogenesis and the formation of metastasis, thus becoming attractive targets in cancer therapy. 
Here, we report our optimization effort to identify novel N-isopropoxy-arylsulfonamide 
hydroxamates with improved inhibitory activity toward MMP-2, MMP-9 and MMP-14 with respect 
to the previously discovered compound 1. A new series of hydroxamates was designed, synthesized 
and tested for their anti-angiogenic activity using in vitro assays with human umbilical vein 
endothelial cells (HUVECs). A nanomolar MMP-2, MMP-9 and MMP-14 inhibitor was identified, 
compound 3, able to potently inhibit angiogenesis in vitro and also in vivo in the matrigel sponge 
assay in mice. Finally, X-ray crystallographic and docking studies were conducted for compound 3 
in order to investigate its binding mode to MMP-9 and MMP-14. 
 
1. Introduction  
Angiogenesis is the formation of new blood vessels from preexisting ones and it is an essential 
feature of tissue remodeling associated with physiological (i.e. wound healing) and pathological 
processes (i.e. solid tumor growth, rheumatoid arthritis, psoriasis). In particular, tumor-induced 
angiogenesis is considered to be important to support growth of solid tumors to the size when they 
become invasive and able to give metastasis1. Without this process of neovascularization tumors 
remain in their dormant form, where proliferation is balanced with apoptosis2. Tumor-induced 
angiogenesis requires degradation of the vascular basement membrane and remodeling of the 
extracellular matrix (ECM) in order to allow endothelial cells to migrate and invade the surrounding 
tissue. 
Matrix metalloproteinases (MMPs) or matrixins are a family of 23 zinc-containing endopeptidases 
that catalyze the cleavage of various components of the ECM. Given their ability to degrade the 
ECM, MMPs involvement in tumor-induced angiogenesis has been extensively investigated. 
Several studies3 have shown that MMPs are involved in the “angiogenic switch”, one of the first 
stages in tumor growth and progression, and also in the maintenance of the growing vascular bed. 
Among all MMPs, MMP-24, MMP-95 and MMP-146 have been shown to be crucial for tumor 
angiogenesis and the formation of metastasis. MMP-14 or membrane-type matrix 
metalloproteinase-1 (MT1-MMP) is particularly important because besides cleaving many 
substrates in the ECM, including type I collagen, it is also involved in MMP-2 activation on the 
surface of invasive tumor cells. These actions combined make this membrane-bound MMP essential 
to promote pericellular proteolysis and invasion7. The importance of MMP-14 as target in cancer 
therapy has been recently validated by a study from Dyax Corporation which used a highly 
selective fully human MMP-14 inhibitory antibody (DX-2400) in a xenograft model of human 
breast cancer expressing high levels of MMP-14 (MDA-MB-231)8. The selective inhibition of 
MMP-14 was able to block tumor growth, to reduce tumor vascularization and to retard the 
formation of metastasis. 
Synthetic MMP inhibitors (MMPIs) have been proposed as suitable antiangiogenic agents to be 
used in cancer therapy, often in combination with cytotoxic drugs, over the last fifteen years. The 
first clinical trials using MMPIs in cancer treatments were largely disappointing due to the fact that 
most trials were conducted on patients with advanced stage disease, when the tumor vasculature 
was already well-established, and to the fact that broad-spectrum MMPIs were used9. Nowadays it 
is widely accepted that selective inhibitors of only those MMPs validated as targets in anticancer 
therapy (i.e. MMP-2, MMP-9 and MMP-14) should be used in order to have efficacy and to avoid 
side effects due to cross-inhibition of anti-target proteases. Successful examples of this strategy are 
represented by SB-3CT10, a selective MMP-2 and MMP-9 inhibitor able to reduce prostate cancer 
metastasis to the bone11 and T-cell lymphoma metastasis to the liver12 in animal models, and cis-
ACCP13 a MMP-2 selective inhibitor with antimetastatic activity. A peculiar case is represented by 
NSC405020, an allosteric selective inhibitor of MMP-14 able to bind the hemopexin domain which 
significantly inhibited tumor growth in an animal model of breast cancer14. 
In our previous papers,15,16 we described the synthesis and biological evaluation of N-isopropoxy-N-
biphenylsulfonylaminobutyl hydroxamic acids as selective inhibitors of MMP-2 and MMP-14 for 
cancer therapy. In particular, compound 1 (ARP101, Figure 1) was found to be a potent 
antiangiogenic agent, being able to block human umbilical vein endothelial cells (HUVEC) 
chemoinvasion at micromolar concentrations. Moreover the same compound, tested on the human 
glioma U87MG cell line, was shown to reduce cell invasion by 48% at nanomolar concentrations17. 
In the present paper, we report our optimization effort to identify novel N-isopropoxy-
arylsulfonamide hydroxamates with improved inhibitory activity toward MMP-2, MMP-9 and 
MMP-14 with respect to 1. Our starting hypothesis was that a simultaneous inhibition of all three 
MMPs involved in tumor-induced angiogenesis could have an increased effect against angiogenesis 
able to block tumor growth. A small series of new ethylamido α-substituted hydroxamates, 2a-g and 
3 (Figure 1), was designed and synthesized. These compounds were tested in vitro on recombinant 
MMPs, and the most promising derivatives were tested in the chemoinvasion assay, in order to 
verify the capability of endothelial cells to invade and digest a reconstituted basement membrane 
(matrigel). Finally, the in vivo antiangiogenic activity of 3 was determined using the matrigel 
sponge assay in mice.  
 
FIGURE 1 HERE 
 
2. Results. 
Design of novel MMPs inhibitors. As already seen18 the N-O-isopropyl substituent (P2’ group, 
Figure 1) was important in order to achieve selectivity over MMP-1, while still maintaining activity 
against MMP-2. For this reason we chose to maintain the N-O-isopropyl group in the new series of 
sulfonamido derivatives. Moreover, the isopropyl substituent in the α position relative to the 
hydroxamate (P1 group) present in 1 was replaced with several N-ethylamido groups because 
changes at this level in similar arylsulfonamidic scaffolds had already given an improved activity 
against the target enzyme, ADAM-17, in previous studies19. In our hypothesis, the proper P1’ 
substituent together with the N-O-isopropyl group should be able to direct the selectivity of the new 
compounds towards the target enzymes, while the presence of P1 substituents of variable size 
should modulate their potency exploiting small changes in the S1 pocket between the different 
MMPs.  
Chemistry. Optically active hydroxamates 2a-g (Scheme 1) were prepared starting from the (S)-α-
hydroxy-tert-butyl-ester 7, which was synthesized as previously described.15 A Mitsunobu 
condensation of sulfonamide 4-618,20 with the alcohol 7 in the presence of diisopropyl 
azodicarboxylate (DIAD) and triphenylphosphine gave the tert-butyl esters (R)-8-10. Tert-butyl 
esters 14a-g were obtained by Pd-catalyzed hydrogenation of 8-10 followed by acylation with 
commercial acyl chlorides, using N,N-diisopropylethylamine (DIPEA) as base. Acid cleavage of 
esters 14a-g yielded carboxylates 15a-g which were finally converted to their corresponding 
hydroxamates 2a-g by condensation with O-(tert-butyldimethylsilyl)hydroxylamine followed by 
acid hydrolysis with TFA. 
 
SCHEME 1 HERE 
 
Hydroxamic acid 3 was synthesized as reported in Scheme 2, starting from the previously described 
alcohol 1619a. A Mitsunobu coupling of sulfonamide 5 with the alcohol 16, gave (R)-tert-butyl ester 
17. Acid cleavage of 17 yielded carboxylic acid 18 which was converted to its O-silylate derivative 
upon treatment with O-(tert-butyl-dimethylsilyl)hydroxylamine. Hydrolysis with trifluoroacetic 
acid of tert-butyl O-silylate provided hydroxamic acid 3.  
 
SCHEME 2 HERE 
 
Biological activity on isolated enzymes. The new hydroxamic acids synthesized (2a-g and 3) were 
tested in vitro on human recombinant MMPs by a fluorometric assay, which uses a fluorogenic 
peptide21 as the substrate. Results are reported in Table 1, together with those already obtained for 
the previously described analogue 1. The compounds were tested on MMP-2, -9 and -14, as 
validated targets in cancer therapy, and MMP-1, considered as anti-target whose inhibition could be 
responsible for some side effects, such as musculoskeletal syndrome, clinically observed with the 
use of broad spectrum MMPIs.22 Selectivity over MMP-3 was also evaluated because this enzyme 
was validated as potential anti-target in cancer therapy.23 Finally, the activity against MMP-13 was 
also taken in consideration, given the recently reported role of this enzyme in promoting tumor 
angiogenesis.24 
The replacement of the isopropyl substituent in the α position relative to the hydroxamate (P1 
group) present in 1 with several N-ethylamido chains (compounds 2a-d) caused a decrease of 
activity against MMP-14. This change did not affect activity against MMP-9 but derivative 2c 
bearing an N-ethylacetoamido group in P1 resulted 2-fold more active than 1 on MMP-2 (Table 1), 
showing an IC50=0.33 nM. Given these promising results, we chose to introduce a para-methoxy 
substituent on the biphenyl moiety (P1’group) present in 2c in order to further increase activity and 
selectivity towards MMP-2 (known to be a deep-S1’ pocket MMP). As expected, the para-methoxy-
analogue of 2c, compound 2e, resulted about 6-fold more active than 1 on MMP-2, with an 
IC50=0.13 nM. In a further attempt to expand the selectivity of action towards MMP-14, as our third 
target for the inhibition of tumor-induced angiogenesis controlled by MMPs, we decided to verify 
the effects of the introduction of a planar and lipophilic group in P1 on the scaffold of 2e in place of 
its acetamido R1 substituent. Therefore derivative 3, bearing an N-ethylphthalimido substituent in 
P1, potentially able to give both hydrophobic π-π stacking interactions with aromatic residues and 
hydrogen bonds with the catalytic site of MMP-14, was synthesized. Actually, compound 3 gave 
the best inhibitory results on MMP-9 (IC50=0.43 nM) and MMP-14 (IC50=3.9 nM) still maintaining 
a sub-nanomolar activity on MMP-2 (IC50=0.67 nM). The activity data on MMP-14 was 
noteworthy, given the lack of nanomolar small molecule MMP-14 inhibitors reported so far in 
literature. Moreover, compound 3 showed a 15-fold increase of activity towards MMP-9 and also an 
improved selectivity over MMP-1 and MMP-3 with respect to the reference compound 1. On the 
contrary, the benzenesulfonamido derivative 2g (R=H) showed a decrease of activity, in the 
micromolar range, against all tested enzymes, probably due to the small size of its P1' group unable 
to properly fit in the S1' pocket of MMPs. This is a peculiarity of our N-O-isopropyl sulfonamido-
based hydroxamates which have already shown different profiles of potency and selectivity25 and 
associated lack of cell toxicity20a,26 with respect to the other well known families of sulfonamide 
hydroxamates. In particular, the use of a short aromatic sulfonamido group is detrimental for this 
class of compounds (high micro-molar activity on all tested enzymes), while in all the other known 
classical sulfonamides (e.g. tertiary and secondary sulfonamides) this type of small substituent is 
often able to maintain nanomolar activities, without selectivity of action.27 
The most promising compounds of this series, 2e and 3, were selected to be submitted to cell-based 
assays in order to prove their antiangiogenic activity, and we used 2g as a negative control. 
 
TABLE 1 HERE 
 
Effect of MMP inhibitors on endothelial cell migration and invasion. The effects of 2e and 3 on 
human umbilical vein endothelial cell (HUVEC) migration were assessed in vitro, and compared to 
those obtained using compound 2g. The assay was performed using a modified Boyden chamber 
where fetal bovine serum (FBS) acted as a chemoattractant. Addition of 0.001 to 10 μM of 
compound 3 and 2e resulted in an inhibition of endothelial cell migration, as compared to 
compound 2g (Figure 2A-C). The strongest and significant (***p<0.001,* p<0.05) inhibitory effect 
on HUVEC migration was exerted by compound 3 in a dose dependent manner. 
 
FIGURE 2 HERE 
 
The effect of 3, 2e and 2g on HUVEC invasion was evaluated using modified Boyden chambers28 
where 8 µm pore-size polycarbonate filters, pre-coated with a reconstituted basement membrane 
(matrigel, 10 mg/mL), were used as a barrier to invasion. Treatment with 2e and 3 significantly 
(***p<0.001, **p<0.01) reduced the FBS-induced HUVEC invasion as compared to 2g, in a dose-
dependent manner (Figure 3A-C). Interestingly, a significant inhibitory effect with 3 was observed 
already at the lower concentration (0.001 μM) (***p<0.001; Figure 3A). 
 
FIGURE 3 HERE 
 
Effect of MMP inhibitors on endothelial morphogenesis in vitro. When cultured in a 3-
dimensional (3D) matrigel layer, HUVECs tend to organize into capillary-like-structures, 
mimicking in vitro the events that occur in vivo during angiogenesis. The addition of compound 3 
significantly interfered with FBS-induced morphogenesis of HUVE cells in a dose dependent 
manner, restraining their ability to organize in a capillary-like network, as observed following 6 h of 
treatment and compared to compound 2e, and 2g (Figure 4A). Quantification of meshes, as a direct 
parameter to measure HUVEC network efficiency, showed a significantly decreased number of 
meshes (***p<0.001, *p<0.05) in cells treated with compound 3 as compared to 2e and 2g (Figure 
4B). 
FIGURE 4 HERE 
 
Effect of MMP inhibitors on MMP-2 and MMP-9 levels by qPCR, western blot (WB) and 
gelatin zymography. The ability of compound 3 to interfere with MMP-2 transcript and protein 
levels was assessed by qPCR and confirmed by WB. Since HUVEC constitutively expressed only 
MMP-2, the cells were pre-stimulated under serum-free condition, with 30 nM PMA (Phorbol-12-
myristate-13-acetate) to promote MMPs production. After PMA pre-treatment, low levels of MMP9 
mRNA were detectable (data not shown). Both MMP-2 protein and mRNA were decreased 
following 24h of treatment with compound 3 (Figure 5A-B).   
To investigate whether compounds 3 and 2e were effectively able to inhibit MMP-2 and MMP-9 
activity, gelatin zymography were performed on conditioned media (CM) obtained either from 
untreated HUVECs, followed by exposition to increasing concentrations of 3, 2e and 2g during the 
zymography, or conditioned media from HUVE cells exposed to the compounds 3 and 2g. As 
shown in Figure 5C-D, both compound 3 and 2e reduced MMP-2 and MMP-9 gelatinase activity in 
a dose-dependent manner, as compared to 2g. Compound 3 showed a strong inhibitory effect 
already at low concentrations. The inhibitory effect of compound 3 starts from 0.001 μM, while for 
compound 2e, which exerted a less pronounced gelatinase activity, inhibition was active from 0.1 
μM. Compound 2g showed no effect on the MMPs activities. We therefore evaluated the ability of 
3 to inhibit MMP-2 and MMP-9 activity directly treating HUVE cells, using 2g as a negative 
control. Cells were treated with 3 and 2g 10 μM for 24 hours, using the same protocol for WB 
analysis. As shown in figure 5E-F-G only compound 3 significantly (**p<0.01) affected MMP 
release and production. 
 
FIGURE 5 HERE 
 
Effects of compound 3 on endothelial cell viability and induction of apoptosis. We explored the 
possibility that compound 3, the most promising compound of this series, could exert non-selective 
toxicity or induce endothelial cell death. We analyzed proliferation by MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assays and by staining with Annexin V and 
7-amino-actinomycin D followed by flow cytometry analysis. No significant inhibition of 
endothelial cell growth was observed at different doses of compound 3 (Figure 6). Hydrogen 
peroxide (200 µM) induced apoptosis in approximately 20% of the cells (both Annexin V and 7-
amino-actinomycin D positive; Figure 7). Cells treated with the inhibitor, even at highest 
concentrations, showed a high percentage (about 85%) of viable endothelial cells and no apoptosis 
(Figure 7). These data suggest that compound 3 does not exert toxicity or induce apoptosis in 
endothelial cells. 
 
FIGURE 6 HERE 
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Effects of compound 3 on angiogenesis in vivo. We used the matrigel sponge assay model29 as a 
rapid and quantitative system for measuring the in vivo the anti-angiogenic activity of compound 3. 
Subcutaneous injection of matrigel produces a three-dimensional pellet that, when associated to 
angiogenic factors, becomes rapidly vascularized. VEGF, TNF-α, and heparin were used as 
angiogenic/inflammatory stimuli mixed with the matrigel, inducing an intense angiogenic reaction, 
as indicated indirectly by hemoglobin content. Addition of increasing concentrations of 3 to this 
mixture inhibited the in vivo angiogenic response (Figure 8A) decreasing hemoglobin content. To 
more precisely quantify the effects of compound 3 on angiogenesis, we quantified the number of 
endothelial cells in the pellets (identified as CD45-/CD31+ cells) by flow cytometry. The plugs 
excised from mice treated with compound 3 at 0.1-1-10 µM, both by adding the compound in the 
plugs and by IP injection (starting at day 0 of matrigel injection), showed significantly (*p<0.05) 
decreased number of CD45-/CD31+ cells in a dose dependent manner, as compared with VTH alone 
(Figure 8 B). 
 
FIGURE 8 HERE 
 
X-ray Crystallography and Molecular Modeling. To get an insight into the binding mode of 
compound 3 into the MMP-9 active site, X-ray crystallography studies were performed in 
comparison with the reference compound 1. 
The structures of three polymorphs of MMP-9 with 1 have been analyzed (Figure 9A). The trigonal 
crystal form (PDB code 4XCT) has not been reported before. The structure has been solved at 1.3 Å 
resolution, with a good refinement statistic (Table 1S, Supp. Information). The other crystal forms 
with two molecules in the MMP-9 asymmetric unit have anisotropy problems not reported for other 
inhibitor complexes. Despite refinement problems, the three polymorphs show that the binding of 1 
is well defined, except variability in the propyl and oxypropyl moieties (Figure 9B). The structure 
of the MMP-9-3 complex (PDB code 4WZV) was determined in the monoclinic space group P21 at 
1.65 Å resolution, with similar cell parameters as one of the structures determined for 1. The 
refinement statistics are reported in Table 1S. The ligand is positioned in strong electron density 
(Figure 9C). The binding in the S1' pocket for the two ligands is identical and the two biphenyl 
rings overlap. Excluding the oxypropyl which in the MMP9 catalytic site, for 1 adopts a different 
orientation from that for 3, there is also significant variation in the positioning of the sulfur oxygens 
between 1 and 3 (Figure 9D). The interaction that the sulfonamide oxygen makes for 1 with the 
protein backbone are at 2.90, 3.43 and 3.11 Å from the amide of Leu 188 and the carbonyl and 
amide of Ala 189, while the distances improve for 3 to 2.75, 3.4 and 3.13, respectively. Only a 
single additional direct hydrogen bond (2.97 Å) is observed between one of the phthaloyl carboxyl 
of 3 and the amide nitrogen of Ala 191 that in the 1 complex is made with a water molecule. The 
second phthaloyl carboxyl of 3 participates in promoting MMP-9 homodimerization, through an 
interaction with Tyr 420 via a water molecule (Figure 9E). The more precise positioning of 3 is 
likely to contribute to its higher affinity for MMP-9. 
 
FIGURE 9 HERE 
 
Since compound 3 showed a high inhibition activity also against MMP-2 and MMP-14, its 
interactions and binding disposition into these two MMPs were evaluated by means of docking 
studies followed by molecular dynamic simulations. The docking results highlighted that the 
binding orientation of the ligand into both MMPs was almost identical to that observed into the 
MMP9-3 X-ray structure. Then, with the aim of verifying the stability of the inhibitor−enzyme 
interactions, the MMP-2-, MMP-9-, and MMP-14-3 complexes were subjected to 5 ns of molecular 
dynamic simulations (Figure 10). The ligand binding disposition suggested by the crystallographic 
structure was very stable for all the three MMPs with an average RMSD of about 1.2 Å, and with 
the maintenance of the lipophilic interactions of the biphenyl moiety inside the S1’ cavity and the 
hydrogen bonds of the sulfonamide portion with the nitrogen backbone of L199 and A200 (MMP-9 
residue number). Differently from that observed from the MMP9-3 X-ray structure, the 
phthalimidic scaffold did not show H-bonds but in all three complexes showed a highly stable π-π 
interaction with the catalytic H243, that should be responsible for the high activity of this 
compound. 
 
FIGURE 10 HERE 
 
3. Discussion and Conclusions.  
In this study, a new series of N-O-isopropyl sulfonamido-based hydroxamates with improved 
inhibitory activity toward MMP-2, MMP-9 and MMP-14 with respect to the previously discovered 
compound 1 was designed and synthesized. Among these compounds, two promising derivatives, 
2e and 3, were identified by fluorometric assays on isolated enzymes and were chosen to be 
submitted to cell-based assays on HUVECs in order to assess their antiangiogenic activity. 2e was a 
nanomolar inhibitor of MMP-2 and MMP-9, while 3 was a sub-nanomolar inhibitor of MMP-2 and 
MMP-9 but also a nanomolar inhibitor of MMP-14 (IC50= 3.9 nM) selective over MMP-1 and 
MMP-3. X-ray crystallographic and docking studies validated the importance of the N-
ethylphthalimido group for a proper positioning of 3 in the catalytic site of MMP-9 and MMP-14. 
First, the ability of the two compounds to inhibit gelatinase activity was evaluated on HUVEC 
conditioned medium derived either from untreated cells, further subjected to MMPI exposition or 
on directly MMPI-treated cells, by gelatin zymography and their efficacy was verified in the 
nanomolar range. Then, these two compounds were tested in the chemoinvasion assay, an in vitro 
model of angiogenesis able to quantify the invasive potential of endothelial cells, and in a 
chemotaxis assay, used to measure the effect of 2e and 3 on HUVEC migration. Compound 2g was 
used as negative control in all these biological assays to prove our starting hypothesis that a 
simultaneous inhibition of all three MMPs involved in tumor-induced angiogenesis could have an 
increased effect against angiogenesis. In fact 2g is MMP-2 inhibitor unable to inhibit MMP-9 and 
MMP-14 in the nanomolar range. From this screening, compound 3 emerged as the most active one, 
being able to block angiogenesis in vitro already at nanomolar concentrations while 2g resulted 
inactive in all assays at the concentrations used. Moreover, 3 confirmed its activity in the matrigel 
sponge model in mice, without exerting toxicity or inducing apoptosis in endothelial cells. Taken 
together, these results supported our starting hypothesis that the simultaneous inhibition of all three 
MMPs (MMP-2, -9 and -14), sparing the anti-targets MMP-1 and -3, can represent an effective way 
to increase the antiangiogenic potential of MMP inhibitors to be exploited for cancer therapy, alone 
or in combination with cytotoxic compounds. Further studies will be necessary to demonstrate the 
efficacy of compound 3 to block tumor growth in human cancer models. 
 
4. Experimental section 
Chemistry. Melting points were determined on a Kofler hotstage apparatus and are uncorrected. 1H 
and 13C NMR spectra were determined with a Varian Gemini 200 MHz spectrometer or a Bruker 
Avance III HD 400 MHz spectrometer. Chemical shifts (δ) are reported in parts per million 
downfield from tetramethylsilane and referenced from solvent references. Coupling constants J are 
reported in hertz; 13C NMR spectra were fully decoupled. The following abbreviations are used: 
singlet (s), doublet (d), triplet (t), double-doublet (dd), broad (br) and multiplet (m). 
Chromatographic separations were performed on silica gel columns by flash column 
chromatography (Kieselgel 40, 0.040–0.063 mm; Merck) or using ISOLUTE Flash Si II cartridges 
(Biotage). Reactions were followed by thin-layer chromatography (TLC) on Merck aluminum silica 
gel (60 F254) sheets that were visualized under a UV lamp and hydroxamic acids were visualized 
with FeCl3 aqueous solution. Evaporation was performed in vacuo (rotating evaporator). Sodium 
sulfate was always used as the drying agent. Commercially available chemicals were purchased 
from Sigma-Aldrich. Combustion analyses on target compounds were performed by our Analytical 
Laboratory in Pisa. All compounds showed >95% purity. See the Supporting Information for 
compound purity analysis data for final compounds.  
General procedure for the preparation of (R)-tert-butyl esters 8-10. Diisopropyl 
azodicarboxylate (DIAD) (1.28 mL, 6.52 mmol) was added dropwise to a solution containing (S)-
tert-butyl 4-(benzyloxycarbonylamino)-2-hydroxybutanoate 7 (0.8 g, 2.61 mmol), the appropriate 
sulfonamide 4-6 (3.91 mmol) and triphenylphosphine (2.05 g, 7.83 mmol) in anhydrous THF (45 
mL) under nitrogen atmosphere at 0 ºC. The resulting solution was stirred for 5h at rt and 
evaporated under reduced pressure to afford a crude product, which was purified by flash 
chromatography on silica gel. 
(R)-tert-Butyl 8-(biphenyl-4-ylsulfonyl)-10-methyl-3-oxo-1-phenyl-2,9-dioxa-4,8-
diazaundecane-7-carboxylate (8). The title compound was prepared from N-isopropoxy-
sulfonamide 4 following the general procedure. The crude was purified by flash chromatography on 
silica gel (n-hexane/EtOAc 5:1) to give a yellow oil (79% yield). 1H-NMR (CDCl3) δ: 1.22-1.25 
(m, 15H); 2.04 (m, 2H); 3.22-3.37 (m, 2H); 4.12 (dd, J= 7.14 Hz, J= 14.29 Hz, 1H); 4.43 (septet, 
J= 6.2 Hz, 1H); 5.08 (s, 2H); 7.34 (m, 5H); 7.42-7.53 (m, 3H); 7.55-7.61 (m, 2H); 7.7-7.74 (m, 2H); 
7.94-7.98 (m, 2H).  
(R)-tert-Butyl 8-(4'-methoxybiphenyl-4-ylsulfonyl)-10-methyl-3-oxo-1-phenyl-2,9-dioxa-4,8-
diazaundecane-7-carboxylate (9). The title compound was prepared from N-isopropoxy-
sulfonamide 5 following the general procedure. The crude was purified by flash chromatography on 
silica gel (n-hexane/EtOAc 5:2) to give a yellow oil (74% yield). 1H-NMR (CDCl3) δ: 1.21-1.32 (m, 
15H); 1.90-2.10 (m, 2H); 3.10-3.50 (m, 2H); 3.86 (s, 3H); 4.06-4.16 (m, 1H); 4.43 (septet, J= 6.2 
Hz, 1H); 5.08 (s, 2H); 6.97-7.02 (m, 2H); 7.34 (m, 5H); 7.51-7.56 (m, 2H); 7.65-7.70 (m, 2H); 
7.90-7.94 (m, 2H). 
(R)-tert-Butyl 8-(4-bromophenylsulfonyl)-10-methyl-3-oxo-1-phenyl-2,9-dioxa-4,8-
diazaundecane-7-carboxylate (10). The title compound was prepared from N-isopropoxy-
sulfonamide 6 following the general procedure. The crude was purified by flash chromatography on 
silica gel (n-hexane/EtOAc 8:3) to give a yellow oil (87% yield). 1H-NMR (CDCl3) δ: 1.19-1.30 (m, 
15H); 1.90-2.10 (m, 2H); 3.10-3.50 (m, 2H); 4.01-4.12 (m, 1H); 4.43 (septet, J= 6.2 Hz, 1H); 5.10 
(s, 2H); 7.36 (m, 5H); 7.64-7.68 (m, 2H); 7.73-7.77 (m, 2H). 
General procedure for the preparation of (R)-tert-butyl esters 11-13. A solution of the 
appropriate Cbz-derivative 8-10 (1.27 mmol) in MeOH (80 mL) was stirred under hydrogen 
atmosphere in the presence of 10% Pd-C (0.20 g) and glacial acetic acid (80 mL) for 17 h at rt. The 
resulting mixture was filtered on celite and the filtrate was evaporated under reduced pressure to 
give the deprotected salt. 
(R)-4-tert-Butoxy-3-(N-isopropoxybiphenyl-4-ylsulfonamido)-4-oxobutan-1-aminium acetate 
(11). The title compound was prepared from Cbz-derivative 8 following the general procedure. 
Brownish oil, 93% yield. 1H-NMR (CDCl3) δ: 1.10 (brs, 9H); 1.20 (t, J= 4.4Hz, 6H); 2.16-2.30 (m, 
2H); 3.16 (m, 2H); 4.34-4.46 (m, 2H); 7.40-7.51 (m, 3H); 7.56-7.59 (m, 2H); 7.71-7.75 (m, 2H); 
8.00-8.04 (m, 2H). 13C-NMR (CDCl3) δ: 21.15; 21.22; 27.72; 36.70; 62.97; 80.03; 82.49; 127.03; 
127.45; 127.59; 127.76; 128.67; 129.14; 130.49; 133.60; 139.30; 146.89. 
(R)-4-tert-Butoxy-3-(N-isopropoxy-4'-methoxybiphenyl-4-ylsulfonamido)-4-oxobutan-1-
aminium acetate (12). The title compound was prepared from Cbz-derivative 9 following the 
general procedure. Brownish oil, 95% yield. 1H-NMR (CDCl3) δ: 1.15-1.27 (m, 15H); 2.04-2.10 
(m, 2H); 3.06 (m, 2H); 3.86 (s, 3H); 4.27 (m, 1H); 4.41 (septet, J= 6.2 Hz, 1H); 6.98-7.02 (m, 2H); 
7.52-7.56 (m, 2H); 7.68-7.72 (m, 2H); 7.95-7.99 (m, 2H). 
(R)-4-tert-Butoxy-3-(N-isopropoxyphenylsulfonamido)-4-oxobutan-1-aminium acetate (13). 
The title compound was prepared from Cbz-derivative 10 following the general procedure. Brown 
foam, 87% yield. 1H-NMR (CDCl3) δ: 1.17-1.33 (m, 15H); 2.17-2.40 (m, 2H); 3.22 (m, 2H); 4.33-
4.50 (m, 1H); 5.04 (septet, J= 6.2 Hz, 1H); 7.53-7.66 (m, 3H); 7.96-8.00 (m, 2H). 
General procedure for the preparation of (R)-tert-butyl esters 14a-g. A solution of the 
appropriate aminium acetate 11-13 (0.59 mmol) in dry DMF (6 mL) was treated with the 
appropriate acyl chloride (0.70 mmol) and i-Pr2NEt (0.20 mL, 1.18 mmol). The reaction mixture 
was stirred at rt for 17h, then was diluted with AcOEt, washed with H2O, dried over Na2SO4 and 
evaporated. The crude was purified by flash chromatography on silica gel. 
(R)-tert-Butyl 4-benzamido-2-(N-isopropoxybiphenyl-4-ylsulfonamido)butanoate (14a). The 
title compound was prepared from aminium acetate 11 and benzoyl chloride following the general 
procedure. The crude was purified by flash chromatography on silica gel (n-hexane/EtOAc 2.5:1) to 
give 14a as a yellow oil (34% yield). 1H-NMR (CDCl3) δ: 1.13 (brs, 9H); 1.23 (d, J= 5.1 Hz, 3H); 
1.26 (d, J= 4.4Hz, 3H); 2.10-2.21 (m, 2H); 3.34-3.50 (m, 1H); 3.80-3.92 (m, 1H); 4.23 (t, J= 7.1 
Hz, 1H); 4.45 (septet, 1H); 7.39-7.59 (m, 10H); 7.69-7.73 (m, 2H); 7.93-7.98 (m, 2H). 
(R)-tert-Butyl 4-methanesulfonamido-2-(N-isopropoxybiphenyl-4-ylsulfonamido)butanoate 
(14b). A solution of 11 (0.30 g, 0.60 mmol) in dry THF (3 mL) was treated with methanesulfonyl 
chloride (0.05 mL, 0.60 mmol) and N-methylmorpholine (0.13 mL, 1.2 mmol). The reaction 
mixture was stirred at rt overnight, then was diluted with AcOEt, washed with H2O, dried over 
Na2SO4 and evaporated. The crude was purified by flash chromatography (n-hexane/AcOEt = 3:2), 
to give 14b (100 mg, 32 % yield) as a yellow oil. 1H-NMR (CDCl3) δ: 1.14 (brs, 9H); 1.20-1.26 (m, 
6H); 2.04 (brs, 2H); 2.95 (s, 3H); 3.29 (brs, 2H); 4.25 (t, J= 7.1Hz, 1H); 4.42 (septet, 1H); 7.43-7.54 
(m, 3H); 7.58-7.62 (m, 2H); 7.74-7.78 (m, 2H); 7.96-8.00 (m, 2H). 
(R)-tert-Butyl 4-acetamido-2-(N-isopropoxybiphenyl-4-ylsulfonamido)butanoate (14c). The 
title compound was prepared from aminium acetate 11 and acetyl chloride following the general 
procedure. The crude was purified by flash chromatography on silica gel (n-hexane/EtOAc 1:1) to 
give 14c as a yellow oil (22% yield). 1H-NMR (CDCl3) δ: 1.19-1.24 (m, 15H); 1.90-2.01 (m, 5H); 
3.13-3.23 (m, 1H); 3.53 (m, 1H); 4.12 (m, 1H); 4.40 (septet, 1H); 6.11 (brs, 1H); 7.41-7.52 (m, 3H); 
7.57-7.61 (m, 2H); 7.72-7.76 (m, 2H); 7.94-7.98 (m, 2H). 13C-NMR (CDCl3) δ: 21.17; 23.48; 
27.76; 36.17; 63.59; 79.80; 82.25; 127.39; 127.52; 128.72; 129.16; 130.14; 133.80; 139.19; 146.84; 
170.22.  
(R)-tert-Butyl 2-(N-isopropoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanoate 
(14d). The title compound was prepared from aminium acetate 11 and 2-phenylacetyl chloride 
following the general procedure. The crude was purified by flash chromatography on silica gel (n-
hexane/EtOAc 2:1) to give 14d as a yellow oil (20% yield). 1H-NMR (CDCl3) δ: 1.10-1.22 (m, 
15H); 1.81-2.05 (m, 2H); 3.00-3.21 (m, 1H); 3.50-3.60 (m, 3H); 3.96 (t, J= 7.5Hz, 1H); 4.38 
(septet, 1H); 7.28-7.37 (m, 5H); 7.43-7.54 (m, 3H); 7.57-7.62 (m, 2H); 7.68-7.73 (m, 2H); 7.80-
7.84 (m, 2H). 
(R)-tert-Butyl 4-acetamido-2-(N-isopropoxy-4'-methoxybiphenyl-4-ylsulfonamido)butanoate 
(14e). The title compound was prepared from aminium acetate 12 and acetyl chloride following the 
general procedure. The crude was purified by flash chromatography on silica gel (n-hexane/EtOAc 
2:3) to give 14e as a yellow oil (42% yield). 1H-NMR (CDCl3) δ: 1.19-1.25 (m, 15H); 1.90-2.04 (m, 
5H); 3.13-3.50 (m, 2H); 3.87 (s, 3H); 4.12 (m, 1H); 4.41 (septet, 1H); 6.99-7.03 (m, 2H); 7.53-7.57 
(m, 2H); 7.69-7.73 (m, 2H); 7.91-7.95 (m, 2H). 
(R)-tert-Butyl 2-(N-isopropoxy-4'-methoxybiphenyl-4-ylsulfonamido)-4-(2-
phenylacetamido)butanoate (14f). The title compound was prepared from aminium acetate 12 and 
2-phenylacetyl chloride following the general procedure. The crude was purified by flash 
chromatography on silica gel (n-hexane/EtOAc 3:2) to give 14f as a yellow oil (24% yield). 1H-
NMR (CDCl3) δ: 1.16-1.25 (m, 15H); 1.90-2.05 (m, 2H); 3.12 (m, 2H); 3.57 (s, 2H); 3.87 (s, 3H); 
3.94 (t, J= 7.5Hz, 1H); 4.37 (septet, 1H); 6.98-7.04 (m, 2H); 7.31-7.37 (m, 5H); 7.52-7.57 (m, 2H); 
7.64-7.68 (m, 2H); 7.77-7.81 (m, 2H). 
(R)-tert-Butyl 4-acetamido-2-(N-isopropoxyphenylsulfonamido)butanoate (14g). The title 
compound was prepared from aminium acetate 13 and acetyl chloride following the general 
procedure. The crude was purified by flash chromatography on silica gel (n-hexane/EtOAc 3:1) to 
give 14g as a yellow oil (55% yield). 1H-NMR (CDCl3) δ: 1.16-1.23 (m, 15H); 1.94 (s, 3H); 3.10-
3.50 (m, 2H); 4.08 (m, 1H); 4.36 (septet, 1H); 7.49-7.69 (m, 3H); 7.87-7.92 (m, 2H). 
General procedure for the preparation of (R)-carboxylic acids 15a-g. Trifluoroacetic acid 
(0.9 mL, 57.00 mmol) was added dropwise to a stirred solution of the appropriate tert-butyl ester 
14a-g (0.21 mmol) in freshly distilled CH2Cl2 (1.0 mL), cooled to 0°C. The solution was stirred for 
5 h at 0°C and the solvent was removed in vacuo to give a crude that was purified by trituration 
with Et2O/n-hexane. 
(R)-4-Benzamido-2-(N-isopropoxybiphenyl-4-ylsulfonamido)butanoic acid (15a). The title 
compound was prepared from tert-butyl ester 14a following the general procedure. Yellow oil, 99% 
yield. 1H-NMR (CDCl3) δ: 1.20 (t, J= 5.1 Hz, 6H); 1.80-2.28 (m, 2H); 3.40-3.55 (m, 1H); 3.60-3.82 
(m, 1H); 4.30-4.50 (m, 2H); 6.56 (brs, 1H); 7.43-7.58 (m, 10H); 7.66-7.69 (m, 2H); 7.91-7.94 (m, 
2H). 
(R)-4-Methanesulfonamido-2-(N-isopropoxybiphenyl-4-ylsulfonamido)butanoic acid (15b). 
The title compound was prepared from tert-butyl ester 14b following the general procedure. White 
solid, 79% yield. 1H-NMR (CDCl3) δ: 1.22 (d, J= 6.2 Hz, 6H); 2.06-2.17 (m, 2H); 2.91 (s, 3H); 3.21 
(brs, 2H); 4.34-4.44 (m, 2H); 7.42-7.53 (m, 3H); 7.61-7.66 (m, 2H); 7.74-7.78 (m, 2H); 7.95-7.99 
(m, 2H). 
(R)-4-Acetamido-2-(N-isopropoxybiphenyl-4-ylsulfonamido)butanoic acid (15c). The title 
compound was prepared from tert-butyl ester 14c following the general procedure. White solid, 
80% yield. 1H-NMR (CDCl3) δ: 1.16 (d, J= 2.01 Hz, 3H); 1.19 (d, J= 2.01 Hz, 3H); 1.92-2.10 (m, 
5H); 3.15-3.60 (m, 2H); 4.20-4.39 (m, 2H); 6.73 (brs, 1H); 7.42-7.52 (m, 3H); 7.59-7.63 (m, 2H); 
7.73-7.77 (m, 2H); 7.93-7.97 (m, 2H); 10.24 (brs, 1H). 
(R)-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanoic acid (15d). The 
title compound was prepared from tert-butyl ester 14d following the general procedure. White 
solid, 70% yield. 1H-NMR (CDCl3) δ: 1.14 (d, J= 3.4 Hz, 3H); 1.17 (d, J= 3.4 Hz, 3H); 1.93-2.10 
(m, 2H); 3.14 (m, 1H); 3.47 (m, 1H); 3.61 (s, 2H); 4.13 (t, J= 7.3 Hz, 1H); 4.33 (septet, 1H); 5.32 
(brs, 1H); 6.14 (brs, 1H); 7.22-7.26 (m, 1H); 7.30-7.37 (m, 4H); 7.42-7.53 (m, 3H); 7.58-7.63 (m, 
2H); 7.67-7.73 (m, 2H); 7.82-7.86 (m, 2H). 
(R)-4-Acetamido-2-(N-isopropoxy-4'-methoxybiphenyl-4-ylsulfonamido)butanoic acid (15e). 
The title compound was prepared from tert-butyl ester 14e following the general procedure. White 
solid, 67% yield. 1H-NMR (CDCl3) δ: 1.15-1.22 (m, 6H); 1.88-2.05 (m, 5H); 3.19-3.35 (m, 2H); 
3.84 (s, 3H); 4.24 (t, 1H); 4.37 (septet, 1H); 6.30 (brs, 1H); 6.96-7.00 (m, 2H); 7.53-7.58 (m, 2H); 
7.67-7.71 (m, 2H); 7.89-7.94 (m, 2H). 
(R)-2-(N-isopropoxy-4'-methoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanoic 
acid (15f). The title compound was prepared from tert-butyl ester 14f following the general 
procedure. White solid, 70% yield. 1H-NMR (CDCl3) δ: 1.15 (d, J= 1.8 Hz, 3H); 1.18 (d, J= 1.8Hz, 
3H); 1.93-2.10 (m, 2H); 3.10 (m, 2H); 3.56 (s, 2H); 3.86 (s, 3H); 4.15 (m, 1H); 4.37 (septet, 1H); 
6.98-7.02 (m, 2H); 7.30-7.39 (m, 5H); 7.54-7.58 (m, 2H); 7.63-7.67 (m, 2H); 7.80-7.84 (m, 2H). 
(R)-4-Acetamido-2-(N-isopropoxyphenylsulfonamido)butanoic acid (15g). The title compound 
was prepared from tert-butyl ester 14g following the general procedure. White solid, 94% yield. 1H-
NMR (CDCl3) δ: 1.18 (d, J= 2.01 Hz, 3H); 1.21 (d, J= 2.01 Hz, 3H); 1.63-1.80 (m, 2H); 1.97 (s, 
3H); 3.15-3.50 (m, 2H); 4.24 (m, 1H); 4.37 (m, 1H); 6.05 (brs, 1H); 7.52-7.72 (m, 3H); 7.90-7.94 
(m, 2H). 
General procedure for the preparation of (R)-hydroxamic acids 2a-g. 1-[3-
(Dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (EDC) was added portionwise (25 mg, 
0.13 mmol) to a stirred and cooled solution (0 °C) of the appropriate carboxylic acid 15a-g (0.087 
mmol) and O-(tert-butyldimethylsilyl)hydroxylamine (12.8 mg, 0.087 mmol) in dry CH2Cl2 (2.2 
mL). After stirring at room temperature overnight, the mixture was washed with water and the 
organic phase was dried and evaporated in vacuo. 
Silyl precursors (0.05 mmol) were then dissolved in dry CH2Cl2 (0.4 mL) and TFA (0.22 mL, 2.8 
mmol) was added dropwise at 0 °C. After 5 h of stirring, TFA was evaporated. The crude products 
were purified by trituration with n-hexane/Et2O to give the desired hydroxamates 2a-g. 
(R)-N-(4-(Hydroxyamino)-3-(N-isopropoxybiphenyl-4-ylsulfonamido)-4-oxobutyl)benzamide 
(2a). The title compound was prepared from carboxylic acid 15a following the general procedure. 
White solid, 60% yield. Mp: 125-127 °C; 1H-NMR (CDCl3) δ: 1.24 (t, J= 6.5Hz, 6H); 1.44-1.69 (m, 
1H); 2.05-2.21 (m, 1H); 3.10-3.50 (m, 2H); 4.20-4.50 (m, 2H); 7.10 (brs, 1H); 7.30-7.55 (m, 10H); 
7.59-7.63 (m, 2H); 7.86-7.90 (m, 2H). 13C-NMR (CDCl3) δ: 21.10; 27.21; 36.80; 60.90; 80.50; 
127.40; 127.65; 128.89; 129.04; 129.14; 129.50; 129.87; 129.96; 132.61; 134.45; 138.80; 146.90; 
167.50; 168.80.   
(R)-4-Methanesulfonamido-N-hydroxy-2-(N-isopropoxybiphenyl-4-
ylsulfonamido)butanamide (2b). The title compound was prepared from carboxylic acid 15b 
following the general procedure. White solid, 60% yield. 1H-NMR (CDCl3) δ: 1.24 (t, J= 6.4Hz, 
6H); 2.01-2.18 (m, 2H); 2.88 (s, 3H); 3.00-3.20 (m, 2H); 4.40-4.48 (m, 2H); 4.88 (brs, 1H); 7.42-
7.53 (m, 3H); 7.62-7.66 (m, 2H); 7.78-7.83 (m, 2H); 7.95-7.99 (m, 2H). 13C-NMR (CDCl3) δ: 
21.18; 27.15; 40.03; 40.25; 60.02; 80.64; 127.46; 127.92; 128.86; 129.13; 129.91; 130.06; 132.40; 
138.82; 147.40; 167.35.   
(R)-4-Acetamido-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)butanamide (2c). The 
title compound was prepared from carboxylic acid 15c following the general procedure. Yellow oil, 
70% yield. 1H-NMR (CDCl3) δ: 1.23 (d, J= 6.7 Hz, 6H); 1.90-2.08 (m, 5H); 3.04-3.35 (m, 2H); 4.22 
(m, 1H); 4.40 (septet, 1H); 6.73 (brs, 1H); 7.42-7.52 (m, 3H); 7.59-7.63 (m, 2H); 7.76-7.80 (m, 
2H); 7.92-7.96 (m, 2H). 13C-NMR (CDCl3) δ: 21.06; 23.18; 27.02; 36.89; 60.05; 80.72; 128.13; 
129.36; 129.70; 130.57; 133.29; 139.74; 147.82; 166.70; 171.80.  
(R)-N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanamide 
(2d). The title compound was prepared from carboxylic acid 15d following the general procedure. 
White solid, 68% yield. Mp= 65-68 °C; 1H-NMR (CDCl3) δ: 1.18-1.32 (m, 6H); 1.83-2.22 (m, 2H); 
3.10-3.28 (m, 2H); 3.48 (s, 2H); 4.11 (m, 1H); 4.39 (septet, 1H); 6.23 (brs, 1H); 7.16-7.36 (m, 5H); 
7.43-7.47 (m, 3H); 7.57-7.61 (m, 2H); 7.67-7.72 (m, 2H); 7.86-7.90 (m, 2H). 13C-NMR (CDCl3) δ: 
21.08; 27.05; 36.72; 43.39; 61.03; 80.04; 127.41; 127.67; 128.86; 129.04; 129.12; 129.48; 129.86; 
129.98; 132.63; 134.46; 138.82; 147.24; 167.20; 172.38.   
(R)-4-Acetamido-N-hydroxy-2-(N-isopropoxy-4'-methoxybiphenyl-4-
ylsulfonamido)butanamide (2e). The title compound was prepared from carboxylic acid 15e 
following the general procedure. White solid, 80% yield. Mp= 83-85 °C; 1H-NMR (CDCl3) δ: 1.20-
1.26 (m, 6H); 1.94-2.04 (m, 5H); 3.02-3.40 (m, 2H); 3.86 (s, 3H); 4.22 (m, 1H); 4.45 (septet, 1H); 
6.09 (brs, 1H); 6.98-7.02 (m, 2H); 7.55-7.59 (m, 2H); 7.71-7.75 (m, 2H); 7.89-7.94 (m, 2H). 13C-
NMR (CDCl3) δ: 21.12; 27.20; 37.16; 55.41; 60.86; 80.42; 114.59; 127.03; 128.58; 129.84; 129.99; 
131.08; 131.66; 146.80; 160.38; 167.72; 172.94. 
(R)-N-Hydroxy-2-(N-isopropoxy-4'-methoxybiphenyl-4-ylsulfonamido)-4-(2-
phenylacetamido)butanamide (2f). The title compound was prepared from carboxylic acid 15f 
following the general procedure. White solid, 77% yield. Mp= 78-80 °C;  1H-NMR (CDCl3) δ: 1.19-
1.22 (m, 6H); 1.94-1.98 (m, 2H); 3.00-3.20 (m, 2H); 3.51 (s, 2H); 3.86 (s, 3H); 4.10-4.16 (m, 1H); 
4.41 (septet, 1H); 5.89 (brs, 1H); 6.97-7.01 (m, 2H); 7.21-7.32 (m, 5H); 7.53-7.57 (m, 2H); 7.65-
7.69 (m, 2H); 7.83-7.87 (m, 2H). 13C-NMR (CDCl3) δ: 21.14; 26.90; 36.94; 43.28; 55.43; 60.83; 
80.45; 114.59; 127.04; 127.53; 128.59; 129.11; 129.55; 129.85; 129.99; 131.08; 131.78; 134.18; 
146.85; 160.41; 167.62; 172.84. 
(R)-4-Acetamido-N-hydroxy-2-(N-isopropoxyphenylsulfonamido)butanamide (2g). The title 
compound was prepared from carboxylic acid 15g following the general procedure. White 
semisolid, 65% yield. 1H-NMR (CDCl3) δ: 1.24 (d, J= 6.4 Hz, 6H); 1.70-1.85 (m, 2H); 1.95 (s, 3H); 
3.01-3.18 (m, 2H); 4.10-4.20 (m, 1H); 4.43 (m, 1H); 6.00 (brs, 1H); 7.55-7.74 (m, 3H); 7.88-7.92 
(m, 2H). 13C-NMR (CDCl3) δ: 21.09; 23.12; 26.90; 37.16; 60.02; 80.60; 127.03; 129.84; 131.80; 
147.20; 164.70; 170.91.  
(R)-tert-Butyl 4-(1,3-dioxoisoindolin-2-yl)-2-(N-isopropoxy-4'-methoxybiphenyl-4-
ylsulfonamido)butanoate (17). Diisopropyl azodicarboxylate (DIAD) (0.4 mL, 2.0 mmol) was 
added dropwise to a solution containing (S)-tert-Butyl 4-(1,3-dioxoisoindolin-2-yl)-2-
hydroxybutanoate 16 (250 mg, 0.82 mmol), sulfonamide 5 (400 mg, 1.24 mmol) and 
triphenylphosphine (645 mg, 2.46 mmol) in anhydrous THF (12 mL) under nitrogen atmosphere at 
0 ºC. The resulting solution was stirred for 5h at rt and evaporated under reduced pressure to afford 
a crude product, which was purified by flash chromatography on silica gel (n-hexane/AcOEt = 2:1), 
to give the desired product as a pale yellow oil (217 mg, 43% yield). 1H-NMR (CDCl3) δ: 1.24-1.29 
(m, 15H); 2.10-2.30 (m, 2H); 3.51-3.74 (m, 2H); 3.87 (s, 3H); 4.06-4.23 (m, 1H); 4.46 (septet, 1H); 
6.98-7.03 (m, 2H); 7.52-7.88 (m, 10H). 
(R)-4-(1,3-Dioxoisoindolin-2-yl)-2-(N-isopropoxy-4'-methoxybiphenyl-4-
ylsulfonamido)butanoic acid (18). Trifluoroacetic acid (1.5 mL, 18.8 mmol) was added dropwise 
to a stirred solution of tert-butyl ester 17 (205 mg, 0.33 mmol) in freshly distilled CH2Cl2 (2.0 mL), 
cooled to 0°C. The solution was stirred for 5 h at 0 °C and the solvent was removed in vacuo to give 
a crude that was purified by trituration with Et2O/n-hexane. White solid, 135 mg, 74% yield. Mp= 
185-187 °C; 1H-NMR (CDCl3) δ: 1.21 (d, J= 6.2Hz, 3H); 1.27 (d, J= 6.2Hz, 3H); 2.10-2.28 (m, 
2H); 3.61 (m, 2H); 3.87 (s, 3H); 4.33 (m, 1H); 4.46 (septet, 1H); 6.98-7.02 (m, 2H); 7.50-7.54 (m, 
4H); 7.65-7.85 (m, 6H). 
(R)-4-(1,3-Dioxoisoindolin-2-yl)-N-hydroxy-2-(N-isopropoxy-4'-methoxybiphenyl-4-
ylsulfonamido)butanamide (3). 1-[3-(Dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride 
(EDC) was added portionwise (65 mg, 0.34 mmol) to a stirred and cooled solution (0 °C) of 
carboxylic acid 18 (130 mg, 0.23 mmol) and O-(tert-butyldimethylsilyl)hydroxylamine (51 mg, 
0.34 mmol) in dry CH2Cl2 (7.0 mL). After stirring at room temperature overnight, the mixture was 
washed with water and the organic phase was dried and evaporated in vacuo. 
Silyl precursor (100 mg, 0.14 mmol) was then dissolved in dry CH2Cl2 (1.0 mL) and TFA (0.6 mL, 
7.9 mmol) was added dropwise at 0 °C. After 5 h of stirring, TFA was evaporated. The crude 
product was purified by trituration with n-hexane/Et2O to give the desired hydroxamate 3 as a white 
solid (61 mg, 77% yield). Mp= 75-76 °C; 1H-NMR (CDCl3) δ: 1.23 (d, J= 6.2Hz, 3H); 1.30 (d, J= 
6.2Hz, 3H); 2.12-2.32 (m, 2H); 3.40-3.53 (m, 2H); 3.88 (s, 3H); 4.02-4.20 (m, 1H); 4.46 (septet, J= 
6.2Hz, 1H); 6.98-7.02 (m, 2H); 7.29-7.39 (m, 2H); 7.42-7.46 (m, 2H); 7.63 (m, 4H); 7.72-7.76 (m, 
2H). 13C-NMR (CDCl3) δ: 21.15; 26.80; 34.75; 55.44; 60.72; 80.08; 114.50; 123.29; 127.03; 
128.63; 129.88; 131.32; 131.81; 132.01; 133.94; 134.23; 146.81; 160.30; 166.85; 168.23. 
MMP inhibition assays. Recombinant human progelatinase A (pro-MMP-2), B (pro-MMP-9), and 
MMP-14 catalytic domain were a kind gift of Prof. Gillian Murphy (Department of Oncology, 
University of Cambridge, UK). Pro-MMP-1, pro-MMP-13 and pro-MMP-3 were purchased from 
Calbiochem. Proenzymes were activated immediately prior to use with p-aminophenylmercuric 
acetate (APMA 2 mM for 1 h at 37 °C for MMP-2, 1 mM for 1 h at 37 °C for MMP-9, 2 mM for 2 
h at 37 °C for MMP-1, 1 mM for 35 min at 37 °C for MMP-13). Pro-MMP-3 was activated with 
trypsin (4.4 μg/mL) for 30 min at 37 °C followed by addition of soybean trypsin inhibitor (61.5 
μg/mL). For assay measurements, the inhibitor stock solutions (DMSO, 10 mM) were further 
diluted in the fluorimetric assay buffer (FAB: Tris 50 mM, pH = 7.5, NaCl 150 mM, CaCl2 10 mM, 
Brij 35 0.05% and DMSO 1%). Activated enzyme (final concentration 0.5 nM for MMP-2, 1.3 nM 
for MMP-9, 1.0 nM for MMP-14cd, 2.0 nM for MMP-1, 0.66 nM for MMP-13 and 5 nM for MMP-
3) and inhibitor solutions were incubated in the assay buffer for 4 h at 25 °C. After the addition of 
200 μM solution of the fluorogenic substrate Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 
(Bachem) in DMSO (final concentration 2 μM), the hydrolysis was monitored every 10 s for 20 min 
recording the increase in fluorescence (λex = 325 nm, λem = 395 nm) using a Molecular Devices 
SpectraMax Gemini XS plate reader. The assays were performed in a total volume of 200 μL per 
well in 96-well microtitre plates (Corning, black, NBS). Control wells lack inhibitor. The MMP 
inhibition activity was expressed in relative fluorescent units (RFU). Percent of inhibition was 
calculated from control reactions without the inhibitor. IC50 was determined using the formula: vi/vo 
= 1/(1 + [I]/ IC50), where vi is the initial velocity of substrate cleavage in the presence of the 
inhibitor at concentration [I] and vo is the initial velocity in the absence of the inhibitor. Results 
were analyzed using SoftMax Pro software30 and GraFit software.31 
Cell cultures 
Human umbilical vein endothelial cells (HUVECs) were purchased from Promo Cell (Heidelberg, 
Germany) and grown on 1% gelatin-coated tissue culture plates in Medium 199 (Sigma Aldrich 
Milano), supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Euroclone, Milano), 
1% glutamine (Euroclone, Milano), fibroblast growth factors (1μg/100mL acid-fibroblast growth 
factor plus 1μg/ 100mL basic-fibroblast growth factor, PeproTech London UK), epidermal growth 
factor (1μg/100mL PeproTech London UK), heparin (10mg/100mL, Sigma Aldrich Milano) and 
hydrocortisone (0.1mg/100mL Sigma Aldrich Milano) at 37 °C in 5 % CO2. Cells were used 
between the third and sixth passage in vitro. 
2x106 cells were seeded in a six-well plate and after one day of attachment, cells were starved 6 h in 
serum-free medium with BSA 2%. Cells were then pre-treated for 3 h with 30 nM PMA, followed 
by exposition to compound 3 or 2g. DMSO was used as vehicle in untreated cells. After 24 hours, 
conditioned media were collected for zymography and cells were processed both for RNA and 
proteins extraction. 
Chemotaxis and chemoinvasion assays. Migration and invasion assays were performed using 
modified Boyden chambers28. Human endothelial cells (HUVEC) (5x104) were washed with PBS, 
resuspended in serum-free medium and placed in the upper compartment of the chamber, in 
presence/absence of different concentrations of inhibitors. Chemoattractant (10% FBS) or serum 
free medium were added in the lower compartment. Pore-size polycarbonate filters (8 μM) were 
pre-coated with collagen (50 µg/mL) or matrigel (1 mg/mL) and used as the interface between the 
two chambers compartments. Following 6 h (migration) or overnight (invasion) incubation, the 
filters were recovered, cells on the upper surface mechanically removed using a cotton swab; cells 
migrated or invaded to the lower filter surface fixed with absolute ethanol and stained with 
Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). Cells were counted in 
a double-blind manner in eight consecutive fields each with a light microscope. All experiments 
were performed three times in duplicate. Statistical significance was determined by One way 
ANOVA using GraphPad Prism. 
Matrigel morphogenesis assay. The in vitro morphogenesis assay was performed in presence of 
10% FBS and different concentration of inhibitors. Briefly, a 24-microwell plate, pre-chilled at -20 
°C, was carefully filled with 300 μL/well of liquid matrigel (10 mg/mL) at 4 °C with a pre-chilled 
pipette, avoiding bubbles. The matrigel was then polymerized for 1 h at 37 °C, and HUVEC 
(50x104 cells/well) were suspended in 1 mL of complete medium in the absence or presence of 
different concentrations of inhibitors and carefully layered on the top of the polymerized matrigel. 
After 6 h incubation on matrigel, the dimensional organization of the cells was examined under an 
inverted microscope (Zeiss, Oberkochen, Germany), equipped with CCD optics and a digital 
analysis system. The number of meshes where measured, as a direct parameter for HUVEC 
tubulogenic efficiency, using the Angiogenesis tool and ImageJ software.32 Statistical significance 
was determined by Oneway ANOVA using GraphPad Prism. 
Quantitative reverse trascription-PCR. Total RNA was extracted from cells using the RNeasy 
Protect Mini Kit (Qiagen, Hilden, Germany) according to the recommendation of the manufacturer 
and reverse transcribed as above with oligo dT primers in 20µL final volume. All primers for the 
genes tested were designed using primer3 software33 with a Tm optimum of approximately 60 °C 
and a product length of 100-150nt. Real time PCR was performed on a LightCycler480 (Roche, 
Penzberg, Germany) using Light Cycler 480 SYBR Green I Master (Roche), 3 µL of cDNA (10x 
diluted), 3 pmol sense and anti-sense primers in a final reaction volume of 10 µL. After an initial 
denaturation step of 5 min during which the well factor was measured, 45 cycles of 10 s at 95 °C 
followed by 15 s at 60 °C and 15 s at 72 °C were performed. Fluorescence was measured during the 
annealing step in each cycle. After amplification melting curves with 80 steps of 15 s and 0.5 °C 
increase were performed to monitor amplicon identity. Expression data were normalized on the 
mean of the expression values for three housekeeping genes: cyclophilin A, 16 s rRNA (ribosomal 
RNA) and GUSB (β-glucuronidase). Relative expression values with standard errors and statistical 
comparisons (unpaired two-tailed t-test) were obtained using Qgene software. 
Western Blot. HUVE cells were grown as indicated and collected by brief trypsinization. Total 
lysates were prepared using cell lysis buffer (Cell Signaling Technology, Beverly, MA). Protein 
concentrations were evaluated by the DC Protein Assay (Bio-Rad, Hercules, CA). Equal amounts of 
proteins for each sample were resolved on 10% sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis and blotted onto polyvinylidene fluoride membranes (Amersham Biosciences, 
Otelfingen, CH). Following blocking with 5% non-fat milk powder (wt/vol) in Tris-buffered saline 
(10 mM Tris–HCl, pH 7.5, 100 mM NaCl, 0.1% Tween-20) for 1 h at room temperature, 
membranes were incubated with primary antibodies directed against the following human antigens: 
MMP-2, MMP-9 (all purchased from Cell Signaling Technology, Danvers, MA) and β-actin (Sigma 
Aldrich, Milan). The antibodies were diluted in 2% bovine serum albumin–Tris-buffered saline–
0.1% Tween according to the manufacturer’s instructions. The bound antibodies were visualized by 
horseradish-peroxidase- conjugated secondary antibodies and an enhanced chemiluminescence 
detection system from Amersham Biosciences (Pittsburg, PA). 
Zymographic Analysis. The effects of compounds on gelatinases activity was determined by gel 
zymography either on MMPs derived from not-treated HUVEC media, further exposed to MMP 
inhibitors or by using CM directly derived from MMP-inhibitors treated HUVE cells. Without 
heating the samples, 20 μL of untreated HUVEC conditioned medium or an equal amounts of 
protein derived from treated HUVECs were loaded 10% polyacrylamide additioned of 0.1% gelatin, 
in presence of SDS. Following electrophoresis, the gels were incubated for 30 min at room 
temperature with gentle agitation in Renaturing Buffer (Invitrogen, Eugene, OR, USA). For 
gelatinase inhibition assays of not-treated HUVEC, the different inhibitors were added in the 
Developing Buffer (Invitrogen, Eugene, OR, USA) over night at 37 °C; the gel slab was cut into 
slices corresponding to the lanes and then put in different tanks containing the stated concentrations 
of inhibitors. For MMPI treated HUVEC, gels were directly incubated over night at 37 °C in 
Developing Buffer. Gels were then stained for 15 min with Coomassie Brillant Blue R-250 stain 
and then de-stained with 10% acetic acid and 30% methanol until sharp bands were visualized. 
Band intensities were quantified by densitometric analysis using ImageJ software (National 
Institutes of Health). 
MTT assay. Human umbilical vein endothelial cell viability was evaluated using the MTT assay. 
Cells (1000/well) were seeded into 96-multiwell plates in complete medium and, after complete 
adhesion, the medium was replaced with fresh medium with or without different concentrations of 
compound 3 (10 nM-10 µM). After different periods of incubation (24, 48, 72 and 96  h), plates 
were processed and absorbance read at 570  nm. 
Assessment of apoptosis by Flow Cytometry. Human umbilical vein endothelial cells (1x105) 
were plated onto six-well plates and allowed to adhere overnight. The next day, cells were treated in 
the growth medium with increasing concentration of the inhibitor (10 nM- 10 µM). Growth medium 
alone (NT) and hydrogen peroxide (100- 200 µM) were used as controls. After overnight, cells were 
recovered, washed with PBS and transferred to test tubes. Cells were pelleted and resuspended in 
Annexin V-binding buffer (0.01 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
pH 7.4; 0.14 M NaCl; 2.5 mM CaCl2). Fluorescein isothiocyanate Annexin V and 7-amino-
actinomycin D (BD Biosciences) were added to each test tube and incubated for 15 min at room 
temperature in the dark. Cells were then washed in PBS, supernatants discarded and resuspended in 
400 mL of binding buffer. Samples were acquired by flow fluorocytometry using a FACSCanto 
(BD Biosciences) and analyzed using FACSDiva Software 6.1.2. 
Matrigel sponge assay (in vivo angiogenesis). The assay was performed as already described29. 
VTH mixture (100 ng/mL VEGF-A, 2 ng/mL TNF-α, and 25 UI/mL heparin), either alone or in 
combination with compound 3 at 0.1-1-10 µM, was added to unpolymerized liquid matrigel at 4 °C 
and the mixture was brought to a final volume of 0.6 mL. The matrigel suspension was then slowly 
injected subcutaneously into the flanks of C57/BL6 male mice (Charles River, Calco [Lecco], Italy) 
with a cold syringe. At body temperature in vivo, the matrigel quickly polymerizes to form a solid 
gel. In some experiments the mice were also treated with 0.1-1-10 µM of compound 3 by 
intraperitoneal (i.p.) injection, at day 0. Groups of 8 mice were used for each treatment. Four days 
after injection, the gels were recovered, weighted, minced and diluted in PBS to measure the 
hemoglobin content with a Drabkin reagent kit (Sigma, St Louis, MO, USA). Part of the pellets 
recovered were assessed for endothelial cell infiltrate quantification by multicolor flow cytometry. 
Briefly, pellets were digested for 1 h in 1 mg/mL Collagenase IV. The cell suspension obtained was 
stained with anti-murine mab as follows: APC-CD45, FITC-CD31, PerCP-CD3, finally analyzed by 
flow cytometry. Endothelial cells in the total cell suspension, gated on FSC/SSC-selected viable 
cells, were quantified as the % of CD31+ cells, on CD45-CD3- gated cells. 
Statistical analysis. Results are showed as mean ± SEM. The significance of differences was 
evaluated with a two-tailed t-test or One way ANOVA test using Prism software (GraphPad 
Software for Science, Inc., San Diego, CA, USA). 
Docking Calculations. The crystal structure of MMP-2 (PDB code 1QIB), MMP-9 (PDB code 
4WZV), and MMP-14 (PDB code 3MA2) was taken from the Protein Data Bank.34 After adding 
hydrogen atoms the three proteins were minimized using Amber 11 software35 and parm03 force 
field at 300 K. The three proteins were placed in a rectangular parallelepiped water box, an explicit 
solvent model for water, TIP3P, was used and the complexes were solvated with a 10 Å water cap. 
Sodium ions were added as counter ions to neutralize the system. Two steps of minimization were 
then carried out; in the first stage, we kept the protein fixed with a position restraint of 500 
kcal/mol•Å2 and we solely minimized the positions of the water molecules. In the second stage, we 
minimized the entire system through 5000 steps of steepest descent followed by conjugate gradient 
(CG) until a convergence of 0.05 kcal/Å•mol. Automated docking was carried out by means of the 
AUTODOCK 4.0 program;36 Autodock Tools37 was used in order to identify the torsion angles in 
the ligand, add the solvent model and assign the Kollman atomic charges to the protein. The ligand 
charge was calculated using the Gasteiger method. 
A grid spacing of 0.375 Å and a distance-dependent function of the dielectric constant were used 
for the energetic map calculations. Using the Lamarckian Genetic Algorithm, the docked compound 
was subjected to 100 runs of the Autodock search, using 500000 steps of energy evaluation and the 
default values of the other parameters. Cluster analysis was performed on the results using an RMS 
tolerance of 2.0 Å and the best docked conformation was taken into account. 
MD Simulations. 
All simulations were performed using AMBER, version 11. MD simulations were carried out using 
the parm03 force field at 300 K. The complex was placed in a rectangular parallelepiped water box. 
An explicit solvent model for water, TIP3P, was used, and the complex was solvated with a 10 Å 
water cap. Sodium ions were added as counterions to neutralize the system. Prior to MD 
simulations, two steps of minimization were carried out using the same procedure described above. 
Particle mesh Ewald (PME) electrostatics and periodic boundary conditions were used in the 
simulation.38 The MD trajectory was run using the minimized structure as the starting conformation. 
The time step of the simulations was 2.0 fs with a cutoff of 10 Å for the nonbonded interaction, and 
SHAKE was employed to keep all bonds involving hydrogen atoms rigid. Constant-volume 
periodic boundary MD was carried out for 500 ps, during which the temperature was raised from 0 
to 300 K. Then 4.5 ns of constant pressure periodic boundary MD was carried out at 300 K using 
the Langevin thermostat to maintain constant the temperature of our system. All the α carbons of 
the protein were blocked with a harmonic force constant of 10 kcal/mol•Å2. General Amber force 
field (GAFF) parameters were assigned to the ligand, while partial charges were calculated using 
the AM1-BCC method as implemented in the Antechamber suite of AMBER 11. The final structure 
of the complex was obtained as the average of the last 3.0 ns of MD minimized by the CG method 
until a convergence of 0.05 kcal/mol•Å2. The average structure was obtained using the ptraj 
program implemented in AMBER 11. 
Crystallization and Structure determination. The expression and purification of MMP-9 was 
carried out as previously described.39 In brief, MMP-9 comprises residues Met109–Gly215 and 
Gln391–Gly444, without the additional fibronectin domains. Plasmids were propagated in the 
Escherichia coli strain XL1-Blue and the recombinant catalytic domains expressed in E. coli cells 
BL21 (DE3 star). The protein was refolded from inclusion bodies, and purified as previously 
described. Acetohydroxamic acid (AHA) 120 mM was added to prevent self-degradation and 
MMP-9 concentrated to 337 μM. Detail for the final crystallization conditions used for growing 
crystals are given in Table 1S for both MMP-9 complexes. Prior to data collection at the Soleil 
synchrotron (St. Aubin, France) on beamline Proxima 1, crystals were transferred to an appropriate 
mixed cryoprotectant solution.40 Data was reduced using XDS41 and the script “xdsme”. The crystal 
of the complex MMP-9●3 belonged to the space group P21 and diffracted to 1.65 Å resolution 
(Table 1S). The structure was solved by rigid body refinement using REFMAC542 build using the 
monomer library sketcher from CCP4 program suite,43 the model rebuilt with COOT44 followed by 
cycles of REFMAC5 and phenix.refine.45 Crystals for the MMP-9●1 complex were grown in three 
different polymophs39 but the first two attempts were unsatisfactory. Crystals in the space 
orthorhombic P21212 with cell parameters a = 74.1 Å, b = 98.5 Å, c = 46.1 at 1.9 Å, resulted in a 
structure with R=26.8% and R-free 35.4% because of anisotropy. The related monoclinic 
enatiomorph, P21 with cell parameters a = 39.9 Å, b = 97.4 Å, c = 46.1, β=111.9° gave data to 1.98 
Å with acceptable refinement statistics, R 19.6% and R-free 26.5%. The best diffraction was 
obtained with stimulated nucleation by streak seeding46 in the trigonal space group because groups 
P3221 with cell parameters a = b = 39.6 c = 163.96 at 1.3 Å (Table 1S).  
 
Accession codes. The crystal structure data for the MMP-9 in complex with 1 and 3 have been 
deposited at Protein Data Bank with accession codes 4XCT and 4WZV, respectively. 
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Figure Captions 
Figure 1: Progression of the SAR: from the reference compound 1 to the antiangiogenic agents 2a-
g and 3. 
Figure 2: Effect of MMP inhibitors 2e and 3 on endothelial cell migration in comparison with 
2g. In the migration assay, HUVECs were seeded into the upper compartment of Boyden chambers 
in the presence or absence of inhibitors, whereas 10% FBS was used as chemoattractant were 
placed in the lower compartment. After 6 h incubation, cells in the upper side of the filter were 
removed, and cells that migrated to the lower surface were fixed, stained and counted. Serum-free 
medium (SFM) was used as negative control. All experiments were performed in triplicate and 
repeated two times. Means ± SEM are shown (***p<0.001,* p<0.05).   
Figure 3: Effect of MMP inhibitors 2e and 3 on endothelial cell invasion in comparison with 
2g. The assay was performed in modified Boyden chambers, as described previously28. HUVECs 
(5×104) were washed with PBS, resuspended in serum-free medium in the presence or absence of 
                                                                                                                                                                  
inhibitors and placed in the upper compartment. Chemoattractant (10% FBS) was added in the 
lower compartment. Pore-size polycarbonate filters (8 μm) were pre-coated with matrigel 
(1 mg/mL). After overnight incubation, the filters were recovered, cells on the upper surface 
mechanically removed and cells invaded the lower filter surface fixed, stained and counted. All 
experiments were performed in triplicate and repeated two times. Means ± SEM are shown 
(***P<0.001, **p<0.01). 
Figure 4: Effect of MMP inhibitors 2e and 3 on endothelial morphogenesis in vitro in 
comparison with 2g. HUVECs were seeded on the top of the matrigel layer previously 
polymerized number of mashes on 24-well plates in presence of the indicated concentrations of 
inhibitors. The formation of capillary-like networks was documented by photography after 6 h (5x 
magnification, A) and number of meshes (B), as an indicator of HUVEC tubulogenic efficiency, 
was determined using the Angiogenesis Analyzer tool, provide by ImageJ (***P<0.001, **p<0.01, 
*p<0.05). 
Figure 5: Effect of 2e and 3 on MMP-2 and MMP-9 activity of endothelial cells in comparison 
with 2g. A: qPCR analysis for MMP-2 on 3 and 2g treated HUVECs Vs control; B: WB analysis on 
MMP-2 production on 3 and 2g treated HUVECs. C-D: Representative zymograms showing 
gelatinase activity of the indicated enzymes on HUVEC conditioned media (CM) subsequently 
exposed to 3, 2e and 2g; E: Representative zymograms showing gelatinase activity of the indicated 
enzymes on CM derived from 3 and 2g treated HUVECs. White bands on dark background 
correspond to enzymed-digested regions. MMP-9 and MMP-2 were identified as their pro- and 
active forms; F-G: Densitometric analysis of zymograms showing relative gelatinase activity. 
Figure 6: Effect of 3 on endothelial cell viability. Cell proliferation was evaluated at fixed times 
(24, 48, 72, 96 h) after the addition of compound 3 to the medium. NT: vehicle; DMSO. Means ± 
SEM are shown. 
                                                                                                                                                                  
Figure 7: Effect of 3 on endothelial cell apoptosis. In the apoptosis assay, HUVECs were treated 
with increasing concentrations of compound 3. Vehicle (DMSO; NT) and hydrogen peroxide 
(H2O2) were used as controls. After 18h, cells were recovered, washed and stained with two 
markers, Annexin V and 7-amino-actinomycin D, used to detect viable, dead or cells undergoing 
apoptosis. The experiment was performed two times and each condition was in duplicate. 
Figure 8: Effect of 3 on angiogenesis in vivo. A cocktail of pro angiogenic factors (VEGF-A, 
TNFα and heparin), either alone (VTH) or in combination with different concentrations of 
compound 3 as indicated, was added into matrigel and injected subcutaneously into C57/BL6 mice. 
Drabkin’s assay showed decreased hemoglobin content in excised plug from treat mice as compared 
to those from untreated (A). Pellets excised form mice treated with 3 at indicated doses, showed a 
significantly (*p<0.05) decreased number of CD31+ endothelial cells, as compared to controls (B). 
Figure 9. Schematic representation of the crystal structures of the MMP-9 catalytic domain 
bound to inhibitors 1 and 3. (A) Overall fold of the catalytic domain with 1 (PDB accession code: 
4XCT) in ochre and the catalytic zinc in purple, with the experimental electron density for the 
ligand (weighted 2Fo-Fc). (B) The three polymorphs provide valuable information about the 
variability in ligand positioning limited to positional variations of the propyl and oxypropyl 
moieties. (C) Electron density for 3 in complex with MMP9 (PDB accession code: 4WZV). (D) 
Variability in the sulfur oxygen positioning between 1 and 3 is noted. The distances are given in the 
insert. (E) An additional direct hydrogen bond is observed between the phthaloyl carboxyl of 3 and 
the amide nitrogen of Ala 191; in the complex with 1 it is replaced by an interaction with a water 
molecule. 
Figure 10. Analysis of the MD simulation of 3 complexed with MMP-2, MMP-9, and MMP-14. 
RMSD analysis of the ligand from the starting model structure during the simulations (upper) and 
minimized average structures of 3 docked into MMP-2, MMP-9 and MMP-14 (lower). PDB codes 
of the starting MMP-2, MMP-9, and MMP-14 crystal structures are 1QIB, 4WZV, and 3MA2. 
                                                                                                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. In vitroa activity (IC50, nM) of N-isopropoxy-arylsulfonamide hydroxamates 
2a-g, 3 and the reference compound 1 on MMPs.  
                                                                                                                                                                  
  
 
Compd R R1 MMP-1 MMP-2 MMP-3 MMP-9 MMP-13 MMP-14 
2a 
 
-COPh 780 1.5 450 9.0 4.6 94 
2b 
 
-SO2CH3 320 1.0 71 8.6 2.2 95 
2c 
 
-COCH3 280 0.33 47 6.5 0.68 41 
2d 
 
-COBn 1300 1.4 120 6.4 1.4 81 
2e 
 
-COCH3 660 0.13 20 2.0 0.58 23 
2f 
 
-COBn 1400 0.37 36 2.9 0.25 25 
2g H -COCH3 26000 590 - 3900 1800 5500 
3   200 0.67 105 0.43 0.19 3.9 
118   490 0.81 50 6.7 4.1 9.8 
aEnzymatic data are mean values for three independent experiments performed in duplicate. SD 
were generally within ±10%.  
 
 
 
 
Scheme 1. Synthesis of N-isopropoxy-arylsulfonamide hydroxamates 2a-ga 
                                                                                                                                                                  
 
a
 Reagents and conditions: (i) PPh3, DIAD, THF; (ii) H2, Pd/C 10%, AcOH, MeOH; (iii) R1Cl, DIPEA, 
DMF; (iv) TFA, CH2Cl2, 0 °C; (v) TBDMSiONH2, EDC, CH2Cl2; (vi) TFA, CH2Cl2, 0 °C. 
 
 
 
 
 
 
 
Scheme 2. Synthesis of N-isopropoxy-4-methoxybiphenylsulfonamide hydroxamate 3a 
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a
 Reagents and conditions: (i) PPh3, DIAD, THF; (ii) TFA, CH2Cl2, 0 °C; (iii) TBDMSiONH2, EDC, CH2Cl2; 
(iv) TFA, CH2Cl2, 0 °C. 
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